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According to the Centers for Disease Control and Prevention, stroke is 
statistically responsible for 1 in every 19 deaths of American citizens.5 Stroke is the 
leading cause of permanent disability due to the fact that it compromises both cellular 
and tissue components of the brain, leading to the formation of a physical void within the 
tissue.  
Current research approaches address the cellular component by injecting stem 
cells into this void; however, extremely low cell engraftment, high injected cell death, and 
overall no matrix regeneration are observed. Additionally, these stem cells do not remain 
committed to a neural lineage. We propose to overcome these obstacles by 
incorporating a tissue engineered niche matrix component to the delivery of such stem 
cells. We hypothesize the implantation of this construct will lead to brain regeneration 
with complete sensory and motor functional recovery. 
Niche neural constructs were successfully created and characterized in vitro. In 
addition to maintaining and supporting the life of induced neural-like cells, seeding 
HADSCs onto these scaffolds yielded spontaneous differentiation and overall extended 
cell viability.  
After implantation into MCAO stroke-afflicted rats for 4 weeks, rats treated with 
niche neural constructs showed significant recovery when compared to stroked controls 
(P<0.05) as early as 2 weeks post-stroke culminating in 98% recovery. Histological 
evidence showed integration of the construct with host tissue, an absence of reactive 
astrocytes, widespread neovascularization, and significant tissue remodeling. 
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Additionally after 4 weeks the implanted cells were still committed to a neuron lineage 
and have remained engrafted to the construct area. Additionally, numerous non-human 
neurons were observed within the construct area, further indicating integration with host 
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 CHAPTER 1: INTRODUCTION AND BACKGROUND 
1.1 Neural Anatomy and Physiology 
The brain is divided into two almost completely symmetric hemispheres. 
Additionally, the brain can be divided into four lobes. Each lobe controls different bodily 
functions, but a complete map of the brain shows that different functions are associated 
with specific anatomical structures. These structures differ in their comprising matrix as 
well as the number and types of neural cells observed. 
1.1.1. Matrix 
Brain matrix can be divided into two categories, grey and white matter. Grey 
matter contains cell bodies, glial  cells,  and  vessels.  It  is  termed  “grey”  due  to  the  lack  of  
myelinated axons, which are characteristically white in color. White matter, then, is 
primarily composed of these myelinated axons as well as glial cells. Functionally, white 
matter is associated with action potentials and thus cognition via intra brain 
communication and body-brain communication. These structural differences allow for 
distinct histological identification between brain regions. Most notably, white mater will 
stain very heavily for myelin while grey matter will not stain. Additionally, white matter 
characteristically appears fragmented compared to grey mater. This fragmentation is 
largely due to the heavy lipid concentration within the matrix.  
Glycosaminoglycans (GAGs) are one of the most well-characterized neural 
extracellular matrix (ECM) components.1  GAGs are proteoglycans composed of a 
protein core with repeated disaccharide units. The polar nature of these molecules 
makes them extremely hydrophilic, functioning as a shock-absorbing material. 
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Additionally, GAGs within the brain function in cell signaling, tissue morphogenesis, 
neuronal cell migration, and axon regeneration.1, 2 Though GAGs are widely present in 
healthy brain tissue, the up-regulation of chondroitin sulfate proteoglycans is a direct 
result of glial scar formation.2 Thus any newly formed neural tissue with both a strong 
GAG presence and activated astrocytes should undergo further phenotypic examination 
as potential glial scarring.   
Collagen and Laminin are notable fibrous components in the brain. Collagen IV is 
the dominating collagen type due to its presence in the basement membrane. Overall, 
fibrous components are not heavily present in the brain.1 However they serve numerous 
functional roles including providing structure, directing cell differentiation and 
proliferation, and aiding in development.1, 3 
1.1.2. Cellular Components 
 
 Figure 1: Astrocytes, microglia, and oligodendrocytes 
are all considered accessory cells to the neurons, which 
are the primary neural cell and function as chemical and 
electrical transport cells. 
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There are four main neural cell types, three of which are categorized as 
accessory cells to the neuron: astrocytes, microglia, and oligodendrocytes. Inactivated 
astrocytes are known for their maintenance of the blood-brain barrier through 
interactions with capillaries. The function of microglia is similar to that of leukocytes. 
Oligodendrocytes are the myelin producing cells within the brain, sheathing axons with 
electrical insulation. Lastly, the neuron is the chemical and electrical signaling cell 
responsible for the transmission of information to and from the brain and all other parts 
of the body. 
1.2 Stroke 
Cerebral ischemia, more commonly known as stroke, is responsible for 11.1% of all 
deaths worldwide.4  According to the Centers for Disease Control and Prevention (CDC), 
stroke is statistically responsible for 1 in every 19 deaths of American citizens, costing 
over $38.6 billion in medical expenses.5 The most alarming statistic of stroke comes from 
a 2011 study conducted by the CDC reporting that over the past 10 years, stroke 
prevalence has increased 40% in those aged under 30, leaving a larger and larger 
population debilitated for a longer period of time.6 
1.2.1 Pathology  
Just this year, the stroke council of the American Heart Association met to create 
what   they   termed   a   “working   definition   of   stroke   for   the   21st century,”   and   they  
determined stroke is brain cell death resulting from oxygen deprivation.7 There are two 
main ways this can occur. In hemorrhagic stroke a cerebral blood vessel leaks or bursts. 
Secondly, in ischemic stroke a blood clot forms within a cerebral vessel. Ischemic stroke 
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is by far the more common, but regardless of type, due to nerve tract decussation, stroke 
symptoms occur contralateral to the damaged tissue.  
 
 
Such clots produce both physical and functional damage. When this damage is 
left untreated extensive tissue necrosis occurs, leading to the formation of a tissue void 
within the neural cavity, as seen in figure 3.8 This extreme body response is largely due 
 
 
Figure 2: There are two main types of stroke. In the first, hemorrhagic, 
blood leaks into brain tissue after the bursting of a vessel. In ischemic 
stroke, there is actual blood clot formation within the cerebral 
vasculature. 
Figure 3: Stroke Progression. CT images showing the progression of lesion formation within 
the neural cavity. Left: the healthy brain. Middle: the brain shortly after stroke.  Right: the 
lesion resulting from the necrosis of stroked tissue areas.   
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 to the fact that the previously mentioned neural cell types, most notably the neuron,  
have limited to no regenerative capacity. When a neuron becomes damaged, the neural 
immune response is initiated which leads to the up-regulation of numerous cytokines 
and the disabling of cell adhesion molecules causing further cell death. Moreover, these 
events activate the astrocytes, initiating the cascades heralded as the inhibitors of neural 
regeneration, the most pressing example being the formation of the glial scar.9  
1.2.2 Clinical Interventions 
Tissue Plasminogen Activator (tPA) is the only drug approved for clinical use in 
treating stroke, and even its use is extremely confined by administration restrictions.   
Additionally, tPA is only effective in the treatment of ischemic stroke. As seen below in 
the current clinical scenario for a stroke patient, the most pressing piece of information is 
if it has been less or greater than three hours since the onset of symptoms. 
 
 
Figure 4: Current clinical scenario for a stroke patient highlighting the 
limitations of the only FDA approved stroke treatment, tPA, as well as 
demonstrating the significance of the three hours immediately following the 
onset of stroke symptoms. 
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tPA can only be administered if it has been less than three hours since symptom 
onset and the patient meets the drug use indications. If it has been more than three 
hours and there is visible damage on a CT or MRI, clot retrieval devices can by 
employed to restore blood flow. However, if it has been more than three hours and there 
is no visible damage, patients are simply moved to supportive care. In all of these cases, 
it is important to recognize that these clinical interventions treat the clot, not the 
functional damage the clot already caused. There is a dire need for solutions that aim to 
restore this physical and functional damage. 
1.3 Treatment Approaches 
Though tPA is the only FDA approved stroke treatment, there are promising 
research initiatives in all stages of development. Most of these methods aim to restore 
cell numbers to pre-ischemic levels through the administration of cells or pre-conditioned 
stem cells. 
1.3.1 Cellular-Focused Approaches 
Cell-focused stroke therapies typically employ neural progenitor cells or non-
embryonic stem cells. The traditionally hypothesized mechanism of action is that these 
cells would migrate to damaged brain areas, and re-populate the area with viable cells 
by differentiating into various neural cell types.    
Neural Progenitor Cells (NPCs)  
Utilizing NPCs is very promising, because they have been proven to differentiate 
into all neural cell types.10 Though recent studies have discovered new sources of NPCs 
in the adult brain, particularly in the sub-ventricular zone, these cells have limited 
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differentiation potential.11 The only true source of neural progenitors is the fetal brain, 
shrouding NPC use in ethical concerns.10  
Stem Cells 
Non-embryonic stem cells, particularly bone marrow derived stromal cells and 
adipose derived stem cells do not have these ethical concerns. They have proven neural 
differentiation potential, and they can be donor specific to avoid rejection via the 
generation of an immune response.12 Strong arguments favoring the use of human 
adipose derived stem cells (HADSCs) are the vast abundance of adipose tissue 
(compared to bone marrow), more tissue can be removed per procedure generating a 




Figure 5: Human Adipose Derived Stem Cells. Lipoaspirate is obtained from the patient, this is 
enzymatically processed to obtain the stromal vascular fraction, and this fraction is plated and 
cultured to obtain the adipose derived stem cells. These stem cells have numerous proven 
differentiation lineages including neural applications. 
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As illustrated above, removed adipose tissue can be enzymatically processed yielding a 
stromal derived fraction, and this fraction can be cultured to obtain the HADSCs.  
The testing of these stem cells in vivo has been widely documented. There are 
two main methods of administration, intravenous and intracranial injection. In both 
cases, stem cell therapies increase the treatment window from 3 hours to 7 or more 
days. Moreover, the behavioral testing results indicate varying degrees of functional 
recovery.16-19 However, overall there is minimal cell retention to the target tissue. One of 
the most notable studies showed only a 1% retention rate to the brain.18 There are also 
reports of extensive cell death, little to no decrease in the size of the lesion cavity, and 
overall poor differentiation. 16-20 
Evaluation of Differentiation 
Unfortunately there is no one marker for neural cells, but there are a handful of 
commonly used markers indicating successful differentiation. The first such marker is 
     
 
Nestin which is a neural progenitor marker.13-15 As figure 6A illustrates it is a cytoplasmic 
marker, and it is known to be minimally expressed by HADSCs.14 Map-2 (figure 6B) is 
A B C 
Figure 6: Commonly used markers of neural differentiation. A) Nestin, a cytoskeletal neural progenitor marker. B) 
Map-2, a cytoskeletal neuron marker. C) GFAP, a cytoskeletal astrocyte marker. Note: GFAP is regularly expressed 
by astrocytes, but it is heavily up regulated post neural injury. 
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also cytosolic as it is the protein responsible for the creation and maintenance of neural 
cell projections.14, 15, 21 It is widely accepted in the literature that Map2 expression 
indicates a cell committed to a neuron lineage. Lastly, GFAP (figure 6C) is a structural 
cytoskeletal marker, and it is widely accepted that GFAP expression indicates an 
astrocyte or astrocyte-like cell.14, 22 
1.3.2 Conditioning-Focused Approaches 
In an effort to enhance the expression of such neural markers, researchers have 
begun chemically treating stem cells through a process known as neural induction.13-15, 
22, 23 It is impossible to reference neural induction without mentioning Woodbury, 
specifically his 2000 publication which is the foundation of all neural induction 
approaches (see figure 7). 24 
The medium used to induce differentiation is referred to as neural induction 
medium (NIM). Neural induction protocols typically differ in the chemical base of the NIM 
utilized for induction. Unfortunately, there is an inverse relationship between induced cell 
viability and success of differentiation.25 Harsh chemicals yield extensive cell death with 
promising differentiation potential, while less intense chemicals yield strong, relatively 
undifferentiated cell populations. A balance of sustained neural differentiation and cell 
viability has yet to be attained.23 As such, in vitro neural induction has a finite life calling 
any in vivo or clinical efficacy of the process into question. To date, neural induction has 







1.3.3 Extracellular Matrix-Focused Approaches    
 Overall, there is no investigation into the incorporation of a matrix component in 
the stroke-treatment field. This is surprising for a two main reasons. Firstly, as previously 
described, stroke compromises neural cells and neural tissue, so an effective treatment 
would need to address both of these components. Secondly, the benefits of the 
incorporation of a matrix are extremely well documented.21, 26-28 
Figure 7: Neural  Induction.  Woodbury’s  2000  publication  can  be  seen  as  the  gold  standard  for  neural  induction,  as  his  




The extracellular matrix is the secretion products of resident cells.26, 27 It is 
biomolecularly tissue-specific, so any slight change in the microstructure can alter 
resident cell phenotype and function.  The ECM is a natural niche environment, meaning 
it contains the cues for cellular migration, proliferation, and differentiation.21, 26-28 More 
notably, it has been proven to induce host tissue remodeling.26 
For these reasons, extracellular matrix is incorporated into an array of 
regenerative approaches including the skin, kidney, lung, as well as other neural fields in 
the form of a gel.21, 29, 30 Figure 8 shows a collagen gel used in traumatic brain injury 
models, and figure 9 illustrates a tissue engineered gel both loaded into the syringe and 




Figure 8: Scanning electron microscopy image of a 
collagen gel utilized in traumatic brain injury models. 
Figure 9: A tissue engineered gel loaded for delivery (left) and reconstituted (right). 
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The appeal of these gels is that their delivery would be minimally invasive.29 However, 
gels are only approximations of the target tissue.21 Therefore, in traumatic brain injury 
models, no real reduction in lesion cavity size and again no proven matrix regeneration 
are observed.16, 30 
 
CHAPTER 2: PROJECT APPROACH 
2.1 Overview 
 The creation of a matrix component that more closely mimics native brain tissue 
and its combination with the previously investigated cellular and induction will create a 
new platform for stroke treatment. For this reason, tissue engineering is the most 
appealing approach to further stroke treatment investigations.  
The goal of tissue engineering is commonly described as creating functional 
substitutes for damaged tissues.31 As illustrated below, the tissue engineering paradigm 
usually involves harvesting target xenogeneic tissues and chemically treating them 
through a process known as decellularization to obtain a matrix component, referred to 
as the scaffold.26, 31-33 Simultaneously, adipose tissue is removed from the patient, and 
the tissue is processed to isolate the HADSCs. These HADSCs are then cultured and 
chemically treated through neural induction producing neural-like cells. These neural-like 
cells can then be seeded back onto the scaffold, and this resulting construct (cells + 








The long-term goal for this project is the creation of a clinical alternative for 
patients suffering from stroke that yields complete functional recovery. Ultimately such a 
recovery involves regeneration of viable native neural tissue in areas compromised by 
stroke. This regenerated tissue will not be immunogenic, will fully integrate with host 
tissue, will maintain properties necessary for neural cell growth and maintenance, and 
will ultimately lead to complete restoration of lost function. The hypothesis being 
examined is that niche tissue-engineered scaffolds reseeded with adipose derived stem 
Figure 10: The tissue engineering paradigm: Porcine brains are chemically treated to obtain a matrix 
component referred to as a scaffold. Simultaneously, adipose tissue is removed from the patient and this tissue 
is processed to obtain the adipose derived stem cells. These cells are chemically treated through neural 
induction and seeded onto the scaffold. The resulting construct is then implanted into the stroke patient 
ultimately retuning living tissue and overall function to the area. 
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cells will, upon implantation, return living neural tissue and restore overall function to 
area compromised by stroke. 
2.2 Specific Aims 
Validating the hypothesis that neural tissue regeneration and therefore functional 
stroke recovery can be achieved through this tissue engineering approach requires the 
successful completion of three specific aims. 
2.2.1 Aim I: Create and Characterize a Tissue-Engineered Neural Scaffold 
 Our goal is to utilize tissue engineering methods to create a neural scaffold that 
will efficiently serve as a biomimetic stem cell niche for the next generation of stroke 
treatment investigations. Through decellularization, we can utilize the native architecture 
of porcine brains to generate niche neural scaffolds. This scaffold should contain an 
intact matrix, be free of cells and DNA, have retained basement membrane proteins.  
2.2.2 Aim II: Analyze Stem Cell Niche Potential of Scaffold In Vitro 
Our goal is to determine if the novel scaffold created and characterized in Aim 1 
is in fact a stem cell niche. Therefore, our scaffold must ultimately mimic native neural 
tissue by producing un-aided neural differentiation and providing a suitable environment 
for sustained neural-like cell survival and maintenance. Most notably, this involves 
retaining high levels of viable cells and ensuring that these cells are retaining their 
neural-like characteristics through protein expression analyses. Additionally, neural cell 





2.2.3. Aim III: Establish Preliminary Efficacy of Niche Constructs In Vivo 
Our goal is to employ the niche neural construct developed in specific aim 2 as a 
stroke treatment that upon implantation, returns living neural tissue and therefore overall 
function to areas compromised by stroke. Short-term, this involves improved motor and 
sensory control; long-term, this involves brain tissue regeneration.  
 
CHAPTER 3: MATERIALS AND METHODS 
3.1 Experimental Methods 
The following protocols were used in the creation and in vitro and in vivo testing 
of our niche neural scaffolds and constructs. 
3.1.1 Decellularization 
Porcine brains were ordered from Animal Technologies Inc. (Tyler, Texas). The brains 
were collected from animals aged 2+ years, and were removed leaving the carotid 
arteries intact. The experimental protocol for immersion decellularization was modified 












3.1.2. Histological Tissue Fixation 
 All tissues to be histologically processed were first fixed in 10% neutral buffered 
formalin. Porcine scaffolds were cut as illustrated in figure 11A prior to tissue to 
processing, embedding in paraffin wax, and sectioning at 5µm. Explanted rat brains 
were cut into coronal thirds such that the implanted materials were confined to the 
middle portion (as illustrated in figure 11B) prior to processing, embedding in paraffin 
wax, and sectioning at 5µm.  
 
 
3.1.3 Hematoxylin and Eosin Sections 
 Hematoxylin and Eosin (H&E) staining is a commonly employed method of 
generic cellular and matrix staining. The hematoxylin stains nuclei and other basophilic 
substances blue, while the eosin stains cytoplasm and tissue elements various shades 
of pink. Slides were stained according to the Richard-Allan™  H&E  protocol  listed  below. 
Figure 11: Orientation of tissues prior to processing. Left, porcine scaffolds and fresh samples 
were cut into 6 relatively equal sections. Right, rat explants were cut such that the implants were 





3.1.4  Masson’s Trichrome Sections 
Masson’s   Trichrome   is   a   staining   method   typically   employed to clearly 
differentiate between collagen, blue, and muscle and fibrous components, red, (cell 
nuclei stain black).   Slides   were   stained   according   to   the   Poly   Scientific   Masson’s  
Trichrome Method listed below. Note that the sections were left in Aniline Blue solution 




3.1.5 Bielschowsky Neural Stain Sections 
The Bielschowsky Lester-King method is a silver staining technique employed in 
the  diagnosis  of  Alzheimer’s  disease  due  to  its  deep  brown  staining  of  senile  plaques.  In 
this case the stain was employed, because it clearly stains nuclei and neuronal axons 
black (This allows analysis of cellular interactions as well as serves as an additional 
decellularization assessment). White and gray matter stain yellow to brown. Sections 
were stained according to the Newcomer Supply Lest-King method which is listed below. 
Note that all glassware was cleaned using Hydrochloric Acid, 0.15% Aqueous Solution 
and rinsed in at least six changes of distilled water prior to use. Sections were developed 




3.1.6 Alcian Blue Sections 
Alcian Blue is a staining method for glycosaminoglycans (GAGs) where cell 
nuclei stain red, cytoplasm stains pink, and GAGs stain blue. Though concentrations and 
types of GAGs change with development, the mature brain retains a large amount of 




3.1.7  Movat’s  Pentachrome  Sections 
Movat’s  pentachrome  is  an  efficient  stain  utilized  to  clearly  differentiate  between  
five common matrix components. This stain is particularly useful in scaffold 
characterization and analysis of tissue development. Cellular nuclei stain black, elastin 
fibers stain purple-black, collagen stains yellow, ground substance (GAGs) stains blue, 





3.1.8 Luxol Fast Blue Staining 
Luxol Fast Blue is a prominent method for staining myelin and Nissil substances 
in neural and spinal tissue sections. In this method, myelinated fibers stain blue and 
Nissil substances and nerve cells stain violet.  
 
3.1.9 Immunohistochemical Examination 
Immunohistochemistry (IHC) is a popular staining method for protein expression. 
Positive staining, indicative of matrix or 
cellular expression of the targeted protein, 
appears brown. All antibody preparations 
were made at the manufacturer (Abcam) 
recommended dilution.  
 
 




3.1.9.1 Manual Method 
Table 1 lists all antibodies used during IHC assays. These same antibodies were 






3.1.9.2 Automated Method (Using the Leica Bond System) 
 The Leica Bond Max instrument preforms automated IHC using the highly 
specific Leica polymer detection system. This method of IHC was used for all explant 
IHC analyses. 
 
3.1.10 Qiagen DNA Purification 
 The Qiagen DNeasy Blood and Tissue Kits is a silica-based DNA purification 
system which prepares DNA samples for both qualitative and quantitative analysis. This 
research employed the protocol for purification of total DNA from animal tissue, listed 





3.1.11 Ethidium-Bromide DNA Agarose Gel Electrophoresis 
Gel electrophoresis separates molecules (in this case DNA) by size and or 
charge. An electric field is applied, and the negatively charged DNA molecules move 
away from the edge of the gel producing bands. The below protocol was used for gel 
preparation and analyses. 
 
3.1.12 Nano Drop 200C Analysis 
Nano Drop 200C utilizes very low volumes of purified DNA to generate 
quantitative DNA measurements through UV absorbance. DNA absorbs light of 
wavelength 260nm. The amount of light absorbed indicates increasing amounts of DNA 




3.1.13 Cellular Maintenance and Seeding 
HADSCs 
HADSCs (Invitrogen) were maintained with the manufacture recommended 
media, MesenPRO. Cells were expanded until passage 3-6 prior to use in these studies. 
HADSCs utilized during the in vivo studies were donated from LaCell LLC, and 
maintained according to the previously described conditions. 
Rat Cortical Astrocytes 
 Astrocytes (Invitrogen) were maintained with the manufacture recommended 
medium, the Astrocyte Growth Medium Bulletkit ®. Astrocytes were expanded up to 
passage 7 prior to use in these studies.     
Cell Seeding 
 All cell types underwent the same drop-wise cell seeding method using their 
respective mediums. Briefly, prior to seeding, cells were re-suspended in the total 
volume of media necessary such that 2mL suspension/well (cells seeded onto plastic) or 
105µL suspension/well (cells seeded onto scaffolds) was pipetted slowly over the top of 
each lyophilized scaffold.   
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3.1.14 Live/Dead Staining 
Live/Dead staining is a common qualitative assessment of cell viability. Calcein 
stains live cells a vibrant green via the enzymatic conversion of Calcein AM within cells 
to Calcein. Ethidium homodimer enters damaged cell membranes and binds to any 
remaining nucleic acids, producing red fluorescence. 
 
3.1.15 Immunofluorescence 
Immunofluorescence is a popular staining method for protein expression. Cells 
that are expressing the protein will fluoresce light at a wavelength dictated by the 
emission spectra of the secondary antibody, in this case green. All antibody preparations 





3.1.16 DAPI Staining 
4', 6-diamidino-2-phenylindole (DAPI) is a popular counterstaining method in 
fluorescent techniques. DAPI binds strongly to certain nucleic acid residues fluorescing 
blue, making it a strong cell nucleus marker. DAPI counterstaining validates positive 
immunofluorescence staining by co-localizing the staining with a cell nucleus. DAPI was 
applied directly onto samples prior to fluorescent imaging. 
3.1.17 2,3,5-triphenyltetrazolium chloride (TCC) Staining 
 
TCC staining is a common method of confirming tissue infarction. TCC salts 
react with dehydrogenase enzymes in cells resulting in a red-purple stain. Infarcted 









3.2 Scaffold Creation and Characterization 
Neural scaffolds were created following the previously described decellularization 
protocol. Prior to use, all scaffolds were rinsed 3x with sterile PBS, followed by an 
overnight rinse in sterile PBS, and 3x rinse with sterile PBS to ensure removal of storage 
buffer prior to use in any assay or histological process. 
Scaffold characterization involved histological examination to ensure removal of 
cellular and DNA containing components as well as confirm the presence of an intact 
extracellular matrix. Additionally, more specific stains were employed to determine the 




Lastly, retention of key basement membrane proteins was examined. Collagen IV 
and Laminin are commonly assessed basal lamina proteins, because as previously 
described, they facilitate cell proliferation, differentiation, adhesion, and viability. 
Additionally, Laminin is a known promoter of neural differentiation and GABAergic cell 
proliferation.3 Retention of these proteins is key in the effort to produce a niche neural 
scaffold, meaning a scaffold that acts as a stem cell niche by promoting unaided 
differentiation of stem cells into neural cells and maintaining the viability and neural-
likeness of these cells.  
3.3 In Vitro Experimentation 
The in vitro experimentation focused on determining the niche stem cell potential 
of our scaffolds. Studies were devised such that potential niche stem cell groups were 
directly compared to induced stem cells groups of similar conditions. Initial studies were 
completed in plastic culture wells to establish base measurements of cell viability and 
successful differentiation. Most preliminarily, the method of inducing cells via neural 
induction was replicated to ensure our results would be comparable to the current 
literature. 
3.3.1 Cells Seeded onto Plastic 
In Vitro Study 1 
To confirm the efficacy of neural induction, human adipose derived stem cells 
(HADSCs, Invitrogen) were seeded into tissue culture well plates at a seeding density of 
1500cells / mm3. Cells were allowed 48 hours to adhere before replacing the MesenPRO 
culture media with NIM. The NIM remained for 4hour, 24 hour, or 5 day time points after 
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which time protein expression for neural markers and cell viability were analyzed through 
immunofluorescence and Live/Dead staining, respectively. Controls for this study 
included HADSCs with no induction step and rat cortical astrocytes (Lonza). All controls 
were seeded at the same density as the test group and allowed 48 hours to adhere. 
After 48 hours, protein expression for neural markers and cell viability were analyzed 
through immunofluorescence and Live/Dead staining, respectively. An outline of the 
study can be seen in figure 12.  
 
 
In Vitro Study 2 
In an effort to determine if the low viability associated with neural induction 
results from a lack of nutrient supply, study 2 was completed following the exact 
Figure 12: Detailed explanation of study 1: cells seeded onto plastic. 
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methods described for the treatment group in study 1, except the NIM was replaced 
daily.  
3.3.2 Cells Seeded onto Scaffolds 
In preparation for cell seeding, sterile scaffolds were cut into 5mm diameter 
punches and spread throughout the base of one 96-well tissue culture plate well. 
Scaffolds were frozen in -80°C overnight prior to lyophilization for 24 hours. 
To allow direct comparisons between groups, the methods of studies 3 and 4 
exactly mirror those of in vitro studies 1 and 2, respectively. A schematic of methods for 




Figure 13: Detailed explanation of study 3: cells seeded onto scaffolds. 
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Study 5  
To determine the stem cell niche potential of the scaffolds, HADSCs were 
seeded into tissue culture well plates at a seeding density of 1500cells / mm3. Cells were 
allowed 48 hours to adhere before replacing the MesenPRO culture media. This culture 
media remained for 4hour, 24 hour, or 5 day time points after which time protein 
expression for neural markers and cell viability were analyzed through 
immunofluorescence and Live/Dead staining, respectively. The positive control for this 
study was rat cortical astrocytes (Lonza). Astrocytes were seeded at the same density 
as the test group and allowed 48 hours to adhere. After 48 hours, protein expression for 
neural markers and cell viability were analyzed through immunofluorescence and 
Live/Dead staining, respectively. A schematic of the test group methods can be seen in 
figure 14. 
 
Figure 14: Detailed explanation of study 5: cells seeded onto scaffolds. 
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Study 6  
In an additional effort to determine if the viability of HADSCs was being affected 
by a lack of nutrient supply, study 6 was completed following the exact methods 
described for the treatment group in study 5, except the MesenPRO was replaced daily.  
 
3.4 In Vivo Experimentation 
3.4.1 Overview 
The goal of the in vivo experimentation was to confirm the niche neural 
construct’s efficacy in stroke treatment. There is no in vitro model for stroke.  Rodents, 
more specifically rats, are the most commonly used animal models for stroke due to the 
similarities between their intracranial circulation system and that of humans, the 
abundance of available neurochemical data, and the lack of rete mirabile.34, 35  
The most widely used animal stroke model is middle cerebral artery occlusion 
(MCAO). This method most commonly involves a mid-line neck incision to expose the 
internal and external carotid arteries followed by suture introduction through the external 
into the internal thereby blocking blood flow through the middle cerebral artery. Transient 
introduction of the suture for a 2-hour period yields the most reproducible infarct while 







 Functional recovery in rodent stroke models has been seen as a result of the 
intracranial administration or intravenous administration of stem cell therapies. 
Intravenous administration tends to fuel cell death as well as lead to unwanted side 
effects in other areas.19 However, both delivery methods show the most promise with 
administration 1 day post-stroke and 7 days post stroke.19, 39 Functional recovery can be 
evaluated   through  a  variety  of   testing  methods,  but  certain   tests  such  as   the   “rotarod”  
and  “water  maze”  are known to yield a larger percentage of false positives due to their 
target of very specific brain regions, while the neural severity scoring system, adhesive-
removal, food grabbing, and limb placement tests have yielded more positive results, 
especially during long-term animal monitoring.17, 19, 40-44 Due to the immune-privileged 
location of the stroked brain, a growing number of studies are employing the use of 
human cells in rodent models without antigenic concerns; this approach also supports 
the eventual adoption of the treatment in a translational research scenario.16, 17, 20, 40, 45  
The in vivo study methods employed in this research were designed to confirm 
our ability to successfully induce stroke in our rodent model, to validate a method for 
Figure 15: Intraluminal suture method of middle cerebral artery 
occlusion to induce stroke. 
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niche   neural   construct   delivery,   and   to   evaluate   animals’   functional   recovery   post-
treatment. All components of the in vivo study were completed in accordance with 
Clemson University AUP2013-032 and IBC2010-28. 
 
3.4.2 Stroke Induction 
  
22 middle-aged female Wistar rats underwent 2 hour transient MCAO via the 
intraluminal suture method (described in detail below).  The sutures employed for 
occlusion were 3-0 monofilament nylon sutures coated with silicon (Docool Corp.) that 
were blunted via introduction into flame prior to insertion.  
  
 
Immediately after closing, 6 rats were euthanized and their brains collected for 
TCC Staining to confirm infarction and to determine an average infarct area. The 
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location of the craniotomy incisions and tissue removal were based off of this average 
infarcted area. 
 
3.4.3 Niche Neural Construct Delivery (Craniotomy) 
 One day post-MCAO, 8 rats underwent niche neural construct implantation via 
craniotomy. Briefly, the top of the head of each rat was shaved prior to making an 
incision in the top of the head. The skin was peeled back, and a 5mm square of bone 
was removed from the skull using a dental drill. Then, light suction was introduced, 




Niche neural constructs were then inserted filling the created void. A piece of 
Surgicel (Ethicon) was placed over the top of the brain. The skin was folded back over 
the skull, and each rat was sutured closed.  




These niche neural constructs were prepareed according to the methods 
described in section 3.3.2. The constructs are representitive of the study 6 group at a 4 
day timepoint.  The only deviation from the previously cited methods was that the 
hunman adipose stem cells were verified to be from male donors and were obtained 
from LaCell LLC.  
 
3.4.4 Behavioral Testing 
 To assess functional recovery post-stroke, all rats underwent behavioral testing 
which consisted of modified neural severity scoring (mNSS). The mNSS is a 
combination of sensory and motor analyses where one point is awarded for abnormal 
function (i.e. a score of 0 indicates perfect function). This examination required no 
training prior to administration. The mNSS was administred the night prior to stroke 
induction, 1 hour post-stroke, and weekly thereafter to obtain baseline measuremets, 
assess immediate functional damage, and monitor functional recovery, respectively. The 




3.4.5 Animal Sacrifice 
Animals were euthanized via deep isoflurane anesthesia followed by 
exsanguination. Death was confirmed through bilateral pneumothorax. Rat brains were 
carefully removed via post-mortem craniotomy and immediately placed in formalin. 
(Note: n=6 brains required for TCC staining were not placed in formailn). 
3.4.6 Explant Analysis 
 Explants were prepared for histology and stained as previously described in 





CHAPTER 4: RESULTS 
 
4.1 Scaffold Creation and Characterization 
Fresh porcine brains were decellularized according to the methods described in 
section 3.1.1. Macroscopic changes from fresh to decellularized specimens are 
observed in figure 17. The decellularized scaffold appeared transparent and showed 
significant mass loss 95.97% ± 0.28 (n=3).  
 
  
Qualitative DNA analysis through Ethidium-Bromide DNA Agarose Gel 
Electrophoresis (figure #17C) shows a significant reduction in DNA from fresh to 
decellularized scaffolds. As seen in figure 18, analysis utilizing the Nanodrop 200C 
quantified this reduction from 818.5 ± 66.4 ng/mg in fresh tissue to 4 ± 4.0 ng/mg in the 
scaffolds (P<0.005). 
Figure 17: Qualitative Scaffold Analysis. A) Fresh porcine brain. B) Decellularized 





IHC for neural proteins was employed as an additional measure of successful 
decellularization. Figure 19 illustrates the complete removal of all Nestin, Map-2, and 













Figure 18: Quantitative DNA Analysis via Nanodrop 200C indicating >99% reduction 
in DNA content from fresh to decellularized tissues.   
Figure 19: Histological Decellularization Confirmation. Complete removal of key neural cell proteins is observed in 
decellularized scaffolds.    
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Further characterization was accomplished through histological staining (figure 
20-22). Through H&E, it was clear the scaffold consisted of an intact matrix and was free 
of   all   cellular   components.   Masson’s   Trichrome   staining indicated the scaffold was 
primarily composed of collagen. The presence of what appeared to be intact blood 
vessels was also observed. Additionally through Bielschowsky staining, complete 




A more in depth understanding of the scaffold composition was obtained through 
Movat’s   Pentachrome   and   Alcian   Blue   staining. Movat’s   Pentachrome   staining   was  
consistent   with   Masson’s   Trichrome   indicating   the   scaffold   is   primarily   composed   of  
collagen. However, significant portions of the scaffold also appeared to stain for ground 
substance, supposedly GAGs, and elastin (figure 21). Alcian blue confirmed the 
Figure 20: Preliminary Histological Characterization. Left, H&E staining indicating scaffolds contained an intact 
matrix  with  no  cellular  remnants.  Middle,  Masson’s  Trichrome  staining  indicating  this  matrix  was  primarily  collagen.  
Right, Bielschowsky neural stain confirming scaffolds did not contain neural fibers.   
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presence of GAGs intermixed with 
other matrix components in fresh 
tissue. Consistent   with   the   Movat’s  
staining, limited GAG fractions, 
primarily near the outer edges of the 



















Figure   21:   Movat’s Pentachrome Staining indicating the 
scaffold, though primarily collagen, had retained elastin and 
ground substance (GAGs).   
Figure  22:  Histological  Examination  Continued.  Left,  Movat’s  Pentachrome  staining  confirming  
the scaffold was primarily collagen matrix. Right, Alcian blue staining indicating there was 




Lastly, the scaffold was examined for retention of key basement membrane 





4.2 In Vitro Experimentation 
4.2.1 Viability Assessment 
 Qualitative assessment of cell viability through Live Dead staining of the positive 
control, astrocytes, showed predominantly viable cells (Figure 24). Quantitative analysis 
Figure 23: Basement Membrane Analysis. Left, IHC for collagen IV and right, IHC for Laminin confirming 
retention of both these key basement membrane proteins within the scaffolds.  
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indicated 87% viable cells after 24 hours of culture in well plates compared to 95% 









Similar assessment of cell viability in the test groups of NIM treated HADSCs at 4 hours 










Figure 25: 4 Hour Viability Assessment. Live Dead staining indicated significant populations of viable cells across all 
test groups.  
Figure 24: Astrocyte Viability Assessment through Live Dead staining indicating 87% viable cells seeded onto 









By 24 hours, the remaining cells were almost all viable. However, overall there were 
fewer cells observed throughout the specimens, particularly the NIM groups seeded into 












Table 1: 4 Hour Quantitative Viability Assessment. There was comparable viability between No NIM and the respective 
NIM groups. Overall, strong viability was observed across all groups.  
Figure 26: 24 Hour Quantitative Viability Assessment. There was an increase in viability between No-NIM and the 
respective NIM groups. Overall, strong viability was observed with the exception of the NIM treated group seeded into 
well plates.  
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Finally by day 5, all NIM groups were greatly compromised compared to non-NIM 
treated groups. In the NIM groups seeded onto plastic, almost no viable cells were 












Table 2: 24 Hour Quantitative Viability Assessment. There was an increase in viability between No-NIM and the 
comparable NIM groups. Overall, strong viability was observed with the exception of the NIM treated group seeded into 
well plates.  
Figure 27: 5 Day Quantitative Viability Assessment. All NIM groups showed extremely compromised viability. Non-NIM 











The quantitative viability for NIM groups is summarized in the below graph. All 
NIM groups where cells were seeded onto scaffolds showed greater cell viability than 
their counterparts seeded onto plastic. Significantly, by 24 hours there was statistical 
difference between scaffold and both plate groups. However, no statistical difference 
was observed between groups seeded onto scaffolds. By day 5 there was a clear 
increase in viability, 36-49% compared to 0-5%, between scaffold-seeded and well plate-
seeded groups. Additionally, the statistical difference between scaffold and both plate 
groups still holds. Most notably, by 5 days regardless of environment, replacing the NIM 





Table 4: 5 Day Quantitative Viability Assessment. All NIM groups were extremely compromised. However, the NIM 
groups seeded onto scaffolds showed significantly increased viability compared to cells seeded into well plates. All 



















4.2.2 Cells Seeded onto Plastic 
 Quality of differentiation was assessed though immunofluorescence for neural 
proteins Nestin, Map-2, and GFAP. Negative controls for all immunofluorescence studies 
are provided in the top left corner of each image.  
 The negative control, HADSCs, seeded into well plates very minimally expressed 
Nestin, expressed nuclear Map-2, and did not express GFAP (See Appendix A). 
Figure 28: NIM Viability Summary. By 24 hours there was statistical difference between scaffold and both 
plate groups. This statistical difference held at 5 days with the addition of statistical difference between the 
scaffold and scaffold replaced group. Significantly, regardless of environment, replacing the NIM yielded 
statistically different (lower) viability. 
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 The positive control, astrocytes, seeded into well plates very minimally expressed 








At 4 hours, NIM induced cells seeded onto plastic minimally expressed Nestin, 
Map-2 expression was beginning to transition from nuclear to cytosolic, and no GFAP 







 By 24 hours, expression of both Nestin and Map-2 had significantly increased. 
Additionally, cells began to express GFAP. Notably, all expression was co-localized with 
Figure 29: Astrocyte Protein Expression on Plastic. Astrocyte controls expressed small amounts of Nestin, no 
cytosolic Map-2, and significant amounts of GFAP. 
Figure 30: Study 1 – Protein Expression at 4 hours. Nestin and Map-2 were minimally expressed by test group cells. 
No GFAP expression was observed.   
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a cell nucleus. There were also indications of morphological changes including the 








By 5 days, expression was virtually non-existent. Additionally, there were almost 








By 4 hours, NIM induced cells where the NIM was replaced daily expressed 
Nestin and cytosolic Map-2. However, no GFAP expression was observed.  
Figure 31: Study 1 – Protein Expression at 24 hours. Expression of all markers was observed. Map-2 expression had 
transitioned from nuclear to cytosolic. Additionally, the development of cytosolic processes was observed.      
Figure 32: Study 1 – Protein Expression at 5 Days. No expression was observed. Additionally, very few viable cell 










By 24 hours, expression of Nestin and Map-2 lessened, but GFAP expression 
was now observed. Across all markers, unfavorable morphological changes were 









 By 5 days, neither marker expression nor viable nuclei were observed. 
 
 
Figure 33: Study 2 – Protein Expression at 4 Hours. Nestin and cytosolic Map-2 expression were observed. However, 
no GFAP expression was observed. 
Figure 34: Study 2 – Protein Expression at 24 Hours. Expression of all markers was visible. No favorable morphological 









4.2.3 Cells Seeded onto Scaffolds 
 The positive control, astrocytes, seeded onto scaffolds very minimally expressed 









For NIM induced cells seeded onto scaffolds at 4 hours, expression of all 
markers was observed. Significantly, MAP-2 expression transitioned from nuclear to 
cytosolic.  
 
Figure 35: Study 2 – Protein Expression at 5 Days. Neither marker expression nor viable nuclei observed. 









 By 24 hours, expression of all markers had been maintained. Significantly, 






 At 5 days, there was still fluorescence indicating expression of all markers. 






Figure 37: Study 3 – Protein Expression at 4 Hours. Expression of all markers was observed.  
Figure 38: Study 3 – Protein Expression at 4 Hours. Expression of all markers was maintained. 




For NIM induced cells seeded onto scaffolds where the NIM was replaced daily, 
expression of all markers was observed at 4 hours. Significantly, MAP-2 expression 







 By 24 hours, expression of GFAP appeared to increase. However, the 
morphological changes and alignment observed in the Nestin and Map-2 staining at 4 








Figure 40: Study 4 – Protein Expression at 4 Hours. Expression of all markers was observed. Significantly, Map-2 
expression was cytosolic. 
Figure 41: Study 4 – Protein Expression at 24 Hours. Expression of all markers was observed. It is unclear if cytosolic 
Map-2 expression was maintained. 
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 By 5 days, very minimal Nestin and GFAP expression were observed. No distinct 









At 4 hours, HADSCs seeded onto scaffolds with no induction step expressed 
Nestin, nuclear Map-2, and minimal GFAP. Additionally, there were clear morphological 








Figure 42: Study 4 – Protein Expression at 5 Days. Minimal expression of Nestin, nuclear Map-2, and GFAP was 
observed. 
Figure 43: Study 5 – Protein Expression at 4 Hours. HADSCs seeded onto scaffolds expressed Nestin, nuclear Map-2, 
and minimal GFAP. Significant morphological changes had occurred, as illustrated by the development of numerous 
cytoplasmic processes in cells staining for Nestin. 
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 By 24 hours, HADSCs were expressing all neural markers (Map-2 expression 
had transitioned to cytoplasmic expression). Significant cytoplasmic processes and 








By 5 days, expression of all markers was maintained and even increased. 









Figure 44: Study 5 – Protein Expression at 24 Hours. HADSCs seeded onto scaffolds expressed all markers and 
continued to show morphological characteristics of neural-like cells.  
Figure 45: Study 5 – Protein Expression at 5 Days. HADSCs seeded onto scaffolds exhibited heightened expression of 




At 4 hours, HADSCs seeded onto scaffolds where the MesenPRO cell culture 
media was replaced daily expressed Nestin, nuclear Map-2, and minimal GFAP. As in 








 By 24 hours, cells were expressing all markers. Map-2 staining had transitioned 








Figure 46: Study 5 – Protein Expression at 4 Hours. HADSCs seeded onto scaffolds expressed Nestin, nuclear Map-2, 
and minimal GFAP. 




Expression of all markers was not only maintained but appeared to increase by 









 Phase contrast images overlayed with the calcein portion of a Live Dead stain 
highlighted these maintained morphological features. Cell bodies as well as cellular 









Figure 48: Study 5 – Protein Expression at 5 Days. An increase in expression of all markers was observed. 
Additionally, cells began to align and maintained morphological changes.   
Figure 49: Cellular Alignment to Scaffold Fibers. Phase contrast images overlayed with the calcein portion of a Live 
Dead stain clearly indicated cells (A) and cellular projections (B) were aligning to scaffold fibers. 
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4.3 In Vivo Experimentation 
4.3.1 Stroke Induction 
 The two hour transient MCAO procedure described in section 3.4.2 was 
completed on all 22 rats. A summary of the operation is seen in figure 50. Briefly, the 
rats were anesthetized, a mid-line neck incision was made, and the glandular tissue was 
retracted to reveal the common, external, and internal carotid arteries. The internal 
carotid artery was clamped and the external carotid was ligated. An incision was made 
into the external carotid and the suture was introduced into the internal carotid via the 
external carotid artery. The clamp was removed and the rat was stapled closed for the 
two hour occlusion period. After 2 hours, the rat was re-anesthetized and opened, the 











Figure 50: MCAO Operation. Two hour transient MCAO was performed on all 22 rats as described in section 3.4.2. 
Briefly, a midline neck incision was made and the common, external, and internal carotid arteries were isolated. After 
ligating the external carotid, a small incision was made and the suture was introduced for a two hour period. After two 
hours the suture was removed to allow reperfusion. 
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 Following MCAO stroke induction, 6 rats were 
euthanized and their brains collected for TCC staining. 
Figure 51 shows a representative TCC stained brain 
section. The pale cream color of the brain visible 
through TCC staining indicated successful stroke 
induction. These staining results yielded the average 
infarcted area and therefore the anticipated location of 
construct implantation illustrated in figure 16. 
 The remaining 16 rats were divided into 2 groups, MCAO control (n=8) and 
treatment (n=8). N=4 control rats and N=2 treatment rats died either during or as a result 
of complications from surgery.  
 
4.3.2 Niche Neural Construct Delivery (Craniotomy) 
 The remaining N=6 treatment group rats underwent niche neural construct 
implantation. N=1 rats experienced an anesthesia related death. Niche neural construct 
delivery was successfully accomplished as described in section 3.4.3. Figure 52 
illustrates this process. Briefly, rats were anesthetized, an incision was made on the top 
of the head, and the skin was retracted. Next, a small ~25mm2 section was removed 
from the skull using a dental drill. Damaged brain tissue was identified, as it was 
texturally different from the healthy tissue. Light suction was introduced to these brain 
areas removing the necrotic tissues. The pre-prepared sterile niche neural constructs 
were introduced into this void. Surgicel was placed over the operated area, and the rat 
was sutured closed. This method allowed for the creation of an injury specific void and 
thus maximal treatment delivery.  
Figure 51: TCC Staining. The cream 
color in the upper right indicated 




















4.3.3 Behavioral Testing 
Behavioral testing was completed as described in section 3.4.4. Figure 53 shows 
the baseline (week -1), post-stroke (week 0), and recovery (up to 4 weeks) of each rat 
surviving to the 4 week time point. Each rat began with perfect function, but this function 
decreased from 4-10 points post-stroke, another indication the rats were successfully 
Figure 52: Niche Neural Construct Delivery via Craniotomy. Construct delivery was accomplished as described in 
section 3.4.3. Briefly, a small ~25mm2 skull fragment was removed and light suction was introduced to the damaged 
brain areas. A Niche neural construct was placed into the created void, Surgicel was placed over this area, and the rat 
was sutured closed.  
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stroked. Over the four week period, the treatment group (purple colors) had an overall 
more consistent and better recovery than the stroke controls (orange colors).  
Figure 53 shows the average mNSS score of each group over the 6 time points. 
Post stroke scores between groups were not statistically different. Over the 4 week 
recovery period, the control group exhibited what appeared to be minimal improvement 
eventually plateauing; however, there is no statistical difference between week 0 and 
any recovery week time point (P>0.1). The treatment group exhibited rapid and 
consistent improvement over 4 weeks. This improvement is statistically different from 
week 0 beginning at the 2 week time point (P<0.05). Similarly, the improvement of the 
treatment group is statistically different from that of the control group beginning at the 2 












Figure 53: mNSS Scores by group. The treatment group is statistically different from the control group beginning 2 weeks 
post stroke (P<0.05). Additionally, though the control group appeared to improve, there is no statistical difference 
between control group scores at any time point (P>0.1). Contrastingly, the treatment group scores became statistically 
different from the week 0 score at the 2 week time point (P<0.05). 
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4.3.4 Explant Analysis 
Control (Stroke) Group 
 Histological analysis showed that at 1 week post stroke, rat brain tissue was 
extremely damaged. The tissue did not stain well, and it showed initial signs of 
degradation. By 4 weeks, most of the tissue had been degraded leaving a void of tissue 



















Figure 54: Control Group Histology. Overall, the tissue looked extremely damaged and stained poorly compared to 
healthy tissues. At 1 week, there were signs of degradation, and by 4 weeks most of the tissue had degraded leaving 
a void.  
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 Figure 55 shows more matrix component specific staining. A similar trend of 



















Treatment Group – 1 Week Matrix Analysis 
 At one week, the implanted niche neural constructs did not show significant 
degradation or change in overall matrix composition.  
Figure 55: Control Group Histology Continued. At 1 week, there were signs of degradation, and by 4 weeks most of 












 Movat’s  Pentachrome  staining   revealed   the  matrix  still  contained  elastin.  Alcian  












Figure 56: Week 1 Treatment Group – Matrix Analysis. Niche neural constructs did not show significant degradation. 
Additionally, the matrix remained almost entirely collagen. 
Figure 57: Week 1 Treatment Group – Matrix Analysis Continued. Niche neural constructs had 
retained elastin, left. At right, new GAG formation was occurring between scaffold edges.  
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Treatment Group – Week 4 Matrix Analysis 
 As seen in H&E staining, by 4 weeks, the constructs had large amounts of tissue 
ingrowth. This tissue appeared extremely disorganized, and it was not primarily 


















Figure 58: Week 4 Treatment Group – Matrix Analysis. There was extensive tissue ingrowth within the constructs. This 
tissue growth did not appear organized, and it was not primarily composed of collagen.  
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 Staining  with  Movat’s  Pentachrome  confirmed   that   the   tissue   ingrowth  was  not  




















Figure 59: Week 4 Treatment Group – Matrix  Analysis  Continued.  Movat’s  Pentachrome  staining  confirmed  the  lack  of  




 Embedded in healthy brain matrix are numerous small blood vessels. As seen in 














 H&E staining of 4 week explants showed a similar network of small diameter 
vessels. Similar to the vasculature of healthy brain tissue, these vessels were 20µm in 
diameter on average. These vessels were distributed rather evenly across the construct, 
and contained red blood cells; no leukocytes were visible within the lumen of these 
vessels.  
 
Figure 60: Healthy Brain Vasculature. Cerebral blood vessels differ in size and orientations, but they are primarily 



















IHC for neural markers Nestin, Map-2, and GFAP revealed both Nestin and Map-
2 staining within the construct regions at 4 weeks. However, no GFAP expression was 
observed. Both Nestin and Map-2 expression appeared in cell bodies as well as in the 
matrix surrounding the cells.  
 
 
Figure 61: 4 Week Construct Vasculature. An evenly distributed network of blood vessels was observed within the 














As illustrated in 
figure 63, quantitative 
assessment of marker 
expression revealed a 
statistical increase in the 
number of cells 
expressing neural markers 
over time, with the 
exception of no GFAP 
expression at either time 
point. 
Figure 62: IHC for Neural Markers. Expression of Nestin and Map-2 was observed throughout the construct area. No 
GFAP expression was seen in the construct.  
Figure 63: Quantitative Neural marker Expression.  Expression of Nestin (P<0.0005) 
and Map-2 (P<0.001) increased from 1 to 4 weeks. No GFAP expression observed at 
either time point. 
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 In depth analysis of cell types present in the construct area at 4 weeks was 
obtained through high magnification of H&E staining. Six prominent cell types were    
 
observed, named A-F. Morphologically similar cells were identified in the healthy brain; 
however, cell type E was not located. Morphological analysis reveals cell types A, B, and 
F match a neuron phenotype. Cell types C and D appeared to be a form of accessory 
cell. Lastly, cell type E appeared to be a leukocyte.  
Figure 64: Cell Phenotype Analysis. Middle, a low magnification H&E image with boxes indicating different cell types 
observed within the construct area. Bottom, high magnification images representative of these cell types. Top, the 
equivalent cell type found within a healthy rat brain. Note: cell type E was not observed in the healthy brain. 
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 In depth analysis was performed on potential neural cell types in an attempt to 























Figure 65: Analysis of Cells of Neuron Phenotype. Through H&E cells morphologically appeared to 
be neurons. Map-2 staining confirms expression of Map-2 is all these cell types. Bielschowsky 
staining confirms cell types A and B possess Nissil bodies. 
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and F are morphologically characteristic of 
neurons. Cell type F, the stereotypically 
recognized neuron has two orientations, 
both are represented in the H&E and Map-
2 stains. These neurons stained very darkly 
and did not necessarily have a visible 
nucleus and or nucleolus. They did have 
visible projections, stained for Map-2 along 
the length of the cell, but they did not stain 
for Nissil bodies. Cell type B is 
characteristic of a cross section of an axon, 
where the axon appears rather centrally 
and is surrounded by Nissil bodies. Both 
cell type A and B tended to have concentric 
Map-2 staining around the cell body. Cell 
type A was significantly larger than the 
other cell types and the nucleus and 
nucleolus were along the periphery.  
 Cells with characteristic accessory 
cell phenotypes underwent similar analysis. 
Morphologically, cell type C was much 
smaller than cell type D. Both of these cells 
were typically found in close proximity to 
cells phenotypically characterized as 
Figure 66: Analysis of Accessory Cell Phenotypes. 
Both cell types did not express Map-2 or GFAP. An 
astrocyte is represented and stained with GFAP to 




neurons. As illustrated in figure 66, neither cell type stained for Map-2 or GFAP.  In 
figure 66, an astrocyte from a healthy brain is represented as the healthy cell for GFAP 
staining to allow comparison between cell types C&D and astrocytes.  
  
HADSCs 
 Explants from both time points underwent double staining immunofluorescence 
for human mitochondria (expressed by the HADSCs) and Map-2 (expressed by HADSCs 














Figure 67: Human mitochondria Map-2 Double Stain. Some individual cells expressed both human mitochondria as 
well as Map-2. A notable amount of cells also solely expressed Map-2.Green indicates Map-2. Red indicates human 
mitochondria. Blue indicates DAPI nuclear staining. 
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Overlays of staining indicated that some individual cells were positive for both Map-2 
and human mitochondria.  However, a notable number of cells expressed only Map-2. 
See Appendix A for additional double staining. 
 
The Interface 
 Analysis of the construct – brain tissue interface revealed no identifiable capsule 
formation. The construct appeared well integrated with the surrounding host tissue. 










Analysis  through  Movat’s  Pentachrome  and  Alcian  Blue  yielded  similar  results.  In  
both  Movat’s  and  Alcian  staining,  some  cells  were  oriented  orthogonal  to  the  interface,  
appearing to bridge the gap between construct and host tissue. Additionally, high 
magnification Alcian Blue staining showed neurons (indicated by arrows) at and on both 
sides of the interface. 
Figure 68: Histological Examination of the Interface. The construct is well integrated with the host tissue with no 



























Figure 69: Histological Examination of the Interface Continued. Some cell bodies were orthogonal to the interface, 
bridging the construct and host tissue. High magnification Alcian Blue staining showed neurons at and on both sides 




IHC for neural markers confirmed that the majority of cells at and on both sides of 
the interface stained positively for Nestin and Map-2. GFAP expression was only visible 










Significantly, there was no evidence suggesting reactive astrocytes had formed a 
glial scar surrounding the construct. The number of astrocytes nearing the interface was 









Figure 70: IHC for Neural Markers at the Interface. The majority of cells at and surrounding the interface expressed 
Nestin and Map-2. Specifically, neurons were visible at the interface (indicated by the box). GFAP expression was 
only observed on the host-tissue side of the interface 
Figure 71: GFAP Expression at the Interface. The number of cells expressing GFAP near the interface (middle) is 
consistent with that of healthy brain tissue (left). (Right) Extremely high levels of GFAP expression near the edge of a 
4 week control group explant.   
79 
 
CHAPTER 5: ANALYSIS AND DISCUSSION 
 
5.1 Neural Scaffolds 
 A neural scaffold was successfully created through the Decellularization of a 
porcine brain. As expected, though this process the scaffold lost significant mass, and 
both qualitative and quantitative analysis confirmed a significant reduction in DNA. 
Additionally, IHC staining for neural cell markers confirmed complete lack of expression 
indicating no cellular or protein remnants in the decellularized scaffolds.  
 Histological characterization of the scaffolds immediately confirmed an intact 
matrix with the absence of all cell bodies,   nuclei,   and   neural   fibers.   Both   Masson’s  
Trichrome   staining   and  Movat’s   Pentachrome   staining   indicated the scaffold’s   primary  
composition was  collagen.  However,  Movat’s  staining   revealed retention of the fibrous 
protein elastin and GAGs (confirmed with Alcian Blue staining).  
 Lastly, IHC for basement membrane proteins confirmed the retention of collagen 
IV and Laminin within the matrix. Staining primarily occurred around what appear to be 
intact blood vessels. All scaffold characterization and analyses support   the   scaffold’s  
ability to serve as a non-cytotoxic niche for stem cells. 
 
5.2 Niche Neural Constructs 
 To  replicate  the  gold  standard  in  neural  induction,  Woodbury’s  NIM  protocol  was  
utilized. This protocol calls for a 24-hour pre-induction step consisting of DMEM, 20% 
fetal   bovine   serum,   and   1mM   β-mercaptoethanol. However, after 24 hours in this 
medium cells had aggregated and detached from the plastic. Subsequent studies did not 
utilize this pre-induction step with seemingly no differentiation repercussions. Woodbury 
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did not monitor cell viability over the course of his study, so our results were compared 
to Safford and Qian, two publications with induction mediums very similar to the one 
utilized in this research. By 5 days, Safford reported 35% viability and by 7 days Qian 
reported 5% viability. The viability results represented in tables 2-4 are slightly lower 
than Safford by 5 days likely due to the fact that Safford did not employ DMSO, a known 
cytotoxic cellular environment, in his induction approach. Overall, the values presented 
in this research fall within close proximity to published results.  
The immunofluorescence results for cells seeded onto plastic showed significant 
morphological changes as early as 24 hours post-induction. Expression of all markers 
was observed at this time point, but due to almost complete cell death it is unknown if 
this expression was maintained to day 5. Overall, the efficacy of the NIM protocol was 
confirmed and a baseline for construct assessments established.    
 To our knowledge, no publication has examined the effect of changing out the 
NIM on a regular basis throughout a short-term study. Our hypothesis was that the 
extremely poor viability associated with NIM induction may be due to a lack of nutrient 
supply, and that the cells may be dying for these reasons and not solely due to the 
harshness of the chemical environment. Our hypothesis was proven false, as replacing 
the NIM resulted in even poorer cell viability. By day 5 statistical difference between NIM 
and NIM replaced groups was observed. Additionally, the overall neural differentiation of 
these cells past 4 hours was quite poor. It is likely that the waning viability of the cells 
contributed to this lack of morphological change and cellular interaction. 
 Since neural induction is a widely characterized and established approach in the 
neural regeneration field, it was necessary to determine if this approach is compatible 
with our neural scaffolds. This also helped establish claims that the scaffold was in fact 
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capable of maintaining neural-like cell life. Scaffolds were successfully seeded with NIM 
induced cells. Initially there was no deviation in cell viability from groups seeded onto 
plastic. However, as early as 24 hours there was statistical difference between the 
viability of cells seeded onto scaffold vs. cells seeded onto plastic. Significantly, over 
90% of these cells had remained viable. Contrary to the established inverse relationship 
between cell viability and quality of induced differentiation, the quality of differentiation of 
these cells was not lessened. From 4 hours to 5 days, expression of all markers had 
been maintained. By 5 days, there is a >8x increase in viability observed when cells are 
seeded onto scaffolds. Again, the success of differentiation was not hindered as a result 
of this viability. Most significantly, the Map-2 expression observed was still cytosolic 
indicating cells were progressing towards a neuron lineage.  
 We then hypothesized that changing out the NIM would have similar negative 
effects seen with cells seeded on plastic, but that the scaffold could mitigate some of 
these effects, still showing an increase in cell viability with less compromised quality of 
differentiation. As figure 28 illustrates, there was similar viability between scaffold 
seeded NIM and scaffold seeded NIM replaced groups at 24 hours, but by 5 days 
statistical difference was observed. However, by 5 days, the scaffold seeded NIM 
replaced group was still 7x greater than either group where cells were seeded onto 
plastic. This indicates that the scaffold does mitigate but not completely alleviate the 
viability limitations of replacing the NIM. The quality of differentiation of these cells was 
also mitigated but not completely maintained. By 5 days, marker expression was faint 
but still present (compared to completely absent in plastic seeded groups), specifically 
cytosolic Map-2 expression was no longer present.  
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 HADSCs with no induction step were seeded onto scaffolds and maintained with 
their manufacture recommended media to examine the stem cell niche potential of the 
scaffold. We hypothesized these cells would show significantly higher viability than any 
of the previous groups at all time points. Some decrease in viability was expected due to 
a lack of nutrient supply. Additionally, the scaffold should promote unaided differentiation 
of the seeded cells into neural-like cells. Viability assessments confirmed only a slight 
decrease in cell viability (to 84%) over the 5 day period. Protein expression analysis 
confirmed expression of all markers as early as 4 hours. By 24 hours this expression 
was maintained and Map-2 expression had transitioned from nuclear to cytosolic. In 
contrast to all previous results, the 5 day time point exhibited the most successful 
differentiation with all markers being expressed at a higher intensity. Additionally, 
significant morphological changes, visible as early as the 4 hour time point, had also 
been maintained. The cells also appeared to exhibit varying forms of alignment. This 
evidence confirms that the previously described tissue engineered scaffold reseeded 
with HADSCs produces a niche neural construct. 
 In an effort to provide optimal conditions for survival of seeded cells, we 
hypothesized that replacing the MesenPRO medium would result in an increase in 
overall cell viability without compromising differentiation, morphology, and alignment. An 
increase from 84% to 93% in cell viability was observed. As expected, the quality of 
differentiation also appeared to increase with each time point, culminating in the most 
promising expression at day 5. By 5 days the cells showed cytosolic expression of all 
markers, significant interaction and alignment, and morphological changes. Interestingly 
this alignment was occurring at the cell body level as well as occurring with the 
projections these neural-like cells are developing. Significantly, this evidence indicates: 
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1) our niche neural construct can produce a >85% viability increase compared to cells 
seeded onto plastic. 2) These cells are more neural-like, showing a higher quality of 
differentiation, cellular alignment, and changed morphology compared to cells seeded 
onto plastic. 3) Successful neural differentiation of HADSCs can occur without the use of 
the potentially cytotoxic or harmful chemicals utilized in neural induction. 
 
5.3 In Vivo Efficacy 
 Stroke was successfully induced and a delivery mechanism for our construct was 
validated. Large amounts of animal death are commonly associated with this procedure, 
and our animal study was no exception. In future studies we anticipate this death rate to 
lower based on surgeon and animal care staff familiarity with the procedure. As 
previously mentioned, treatment delivery typically occurs at one day or seven days post 
stroke. In future studies, employing a 7 day time point may provide the animals with 
more recovery time, further improving the survival rate. The construct implantation was 
ultimately more patient-specific than initially anticipated. Though the average infarcted 
area determined by TCC staining was used as a general location for implantation, the 
distinct textural differences between healthy and damaged brain tissue allowed for more 
targeted treatment delivery.  
 Behavioral testing indicated the success of this treatment method from a 
sensory/motor functional recovery perspective. Stroke controls did not show any 
statistical improvement (P>0.1) over the 4 week period. Not only did the treatment group 
show statistical improvement, but also this improvement was statistically different from 
control rats as early as 2 weeks post stroke (P<0.5). It is also important to note that there 
was no statistical difference in the week 0 mNSS scores between groups (P>0.1). Most 
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significantly, the treatment group exhibited almost complete recovery by 4 weeks. It is 
important to note that complete recovery indicates perfect completion of the mNSS 
analysis; it is not a statement of complete return of all sensory or motor functions. More 
behavioral tests would be necessary to understand exactly which types of functions have 
completely recovered and which have not. 
 Histological examination of the stroke group revealed a visibly damaged area at 
1 week post stroke. This tissue was extremely fragmented and overall does not stain 
well – indicating significantly compromised tissue health. There is also significant 
hemorrhage observed throughout this area. As dictated by the previously described 
stroke pathology, this damaged tissue area eventually degraded resulting in a physical 
void within the brain. This has been reported as early as 7 days in rat models.16 In our 
study, this characteristic behavior was observed in the presented stroke controls by 4 
weeks.    
 At 1 week post craniotomy, the treatment group showed significant cell presence 
throughout  the  construct.  Masson’s  Trichrome  and  Movat’s  staining  confirmed very little 
remodeling had occurred, as the majority of the construct was still comprised of 
collagen. Some red blood cells remaining from stroke or craniotomy-related hemorrhage 
were also observed. Alcian Blue staining showed initial tissue ingrowth occurring 
between the folds of the construct; this tissue was almost exclusively GAGs.  
 Extensive and widespread tissue ingrowth occurred by 4 weeks. This tissue 
appeared not well organized and was heavily populated by cells. The composition of this 
newly formed matrix was not collagen, indicating a degree of scaffold degradation prior 
to tissue ingrowth. Significantly, there was a large amount (relatable to fresh tissue) of 
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GAG formation. Overall, this newly formed tissue greatly resembles granulation tissue, 
the initial tissue type formed during the wound healing process. 
 The large population of cells necessitated an examination of neovascularization 
within the construct area to determine if these cells were getting oxygen and general 
nutrient supply. As figure 61 illustrates, vessels primarily 20µm in diameter were widely 
spread throughout the newly formed matrix within the construct area. These vessels 
showed distinct endothelial cell linings with a lumen filled with red blood cells, a strong 
indication of the biocompatibility and integration of the construct by the host.  
 Further indications of integration and maintenance of the construct area as a 
viable tissue result from in depth analysis of the cell types observed in this area. 
Numerous cells throughout the construct stained positively for Nestin and Map-2, 
indicating cells committing to neuron lineages. Interestingly, expression of both these 
markers increases from 1 to 4 weeks. This could support the mechanism proposed by 
Borlongan that stem cells act as bridges, providing a pathway for host neural cells to 
migrate into damaged tissue areas. Contrastingly, no cells stain for GFAP confirming 
that this area is not a host to reactive astrocytes and therefore no further analysis 
relating to glial scarring was done. However, another measure to increase the validity of 
this claim would be analysis of chondroitin sulfate.  
 Figure 64 shows an in depth analysis of the representative cell types populating 
the scaffold area. Cell type A contains a larger cell body with a non-centered nucleus 
and a visible nucleolus. These cells express Map-2 and contain Nissil bodies indicating 
these cells are in fact a neuron. However, these cells were not observed in high 
populations. Cell type B is very characteristic of a neuron. These cells contain Nissil 
bodies, express Map-2 in a concentric ring around the cell body, and have a centrally 
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located axon (in cross section). These cells were observed consistently throughout the 
construct area and are overall one of the largest cell populations. Cell type F is the 
stereotypical neuron. This neuron has numerous orientations including a darkly staining 
area with or without a distinct nucleus/nucleolus. Additionally, the extensions of these 
cells are visible in some orientations. These cells do stain positively for Map-2, but no 
Nissil bodies are seen due to their orientation and dark staining.  
Cell types C and D are both found in near proximity to the previously described 
neurons. These cells appear to have no cytoplasm; they appear as one small (type C) or 
large (type D) nucleus. Morphologically, these cells mimic accessory cell phenotypes. 
Lack of Map-2 staining confirms these cells are not neurons, and lack of GFAP staining 
indicates these cells are not astrocytes. They could be oligodendrocytes or another form 
of accessory cell. Further analysis is required to confirm the identity of these cells. 
The presence of cell type F clearly indicates leukocytes have been recruited to 
the construct area. These cells are presumably macrophages, recruited to degrade the 
scaffold in the initial phases of a wound healing response ultimately leading to tissue 
remodeling and regeneration. IHC for rat macrophages confirmed a macrophage 
presence (not shown). Importantly, no foreign body giant cells were observed anywhere 
in the explanted tissue at either time point, a strong indicator of biocompatibility. This 
also supports that the macrophages are present from remodeling mechanisms vs. 
chronic inflammatory mechanisms.  
 The fate of the implanted HADSCs was examined through identification and 
staining of human mitochondria. Figure 67 illustrates that populations of the HADSCs 
have remained engrafted in the construct area. Though the exact amount of cells was 
not quantified, there was significant engraftment and retention of these implanted cells to 
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the damaged area. Most significantly, these cells still express Map-2, indicating these 
cells have committed to a neuron lineage. To our knowledge this is the first data 
supporting sustained neural differentiation of stem cells in a stroke animal model. Neural 
induction has been previously confirmed in traumatic brain injury models; however, the 
success refers to cells that have committed to a neural but non-neuron phenotype (i.e. 
astrocytes, oligodendrocytes, and microglia). To our knowledge, this is the first data 
supporting injected cell commitment to a neuron lineage over a 4 week period. A notable 
amount of Map-2 expression co-localized with cell nuclei (but not co-localized with 
human mitochondria staining) is observed throughout the construct area. This is another 
indication that this research supports implanted cells recruiting host neural cells via 
paracrine effects. However, as previously mentioned, HADSCs have maintained neural 
protein expression and remained in the construct area indicating that mechanistically the 
HADSCs’  functions  are  beyond  strictly  paracrine. 
 Histological analysis of the interface served as a final assessment of construct 
integration and biocompatibility. Overall, there were no indications of fibrous 
encapsulation. There is no gap between the host tissue and construct tissue. There is a 
strong presence including cells that are oriented orthogonal to the interface. The area is 
contains extensive cell populations including neurons. Cells on both sides of the 
interface express Nestin and Map-2 indicating a strong neuron and neural cell presence 
in the area. No GFAP expression was observed within the construct and the quantities of 
GFAP positive cells on the host side of the interface was consistent with the numbers 
found in healthy brain tissue. More in depth examination of the host-side of the interface 
reveals no glial encapsulation, indicating the scaffold is not contributing to or promoting 
anti-regenerative astrocyte activity. Lastly, this are is well vascularized (see figure 68).  
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CHAPTER 6: CONCLUSIONS 
 
A novel neural scaffold was successfully created and characterized using a 
tissue engineering approach. Specifically this scaffold showed an intact matrix, almost 
no DNA remnants, no cellular remnants, and retained basement membrane proteins.  
In vitro cell seeding studies confirmed the ability of this scaffold to support and 
maintain the viability and neural protein marker expression of both NIM-induced and 
non-induced cell types up to 5 days. Most significantly, the scaffold does promote the 
unaided differentiation of HDSCs into cells of great neural likeness and maintains these 
cells, indicating the scaffold is in fact a stem cell niche.  
Niche neural constructs were successfully implanted into stroke-afflicted rats 
resulting in significant sensory/motor functional recovery as well as the continual support 
of life and neural likeness of HADSCs as well as host neural cells. After 4 weeks, 
implanted HADCSs remained in the construct area and appeared to be committed to a 
neuron lineage. To our knowledge, this is the first evidence suggesting significant 
retention of implanted stem cells to damaged stroke areas as well as the first evidence 
validating neural induction in animal stroke models. There was significant evidence 
suggesting this construct was integrating with host tissue. There was no evidence of 
fibrous encapsulation at the interface, which was vascularized and the host of numerous 
neurons among other cell types. Additionally, the construct had begun to degrade to 
make way for a newly formed vascularized neural matrix. Overall, these results support 




CHAPTER 7: RECOMMENDATIONS  
Though the niche potential of this scaffold was confirmed to 5 days, longer 
studies are needed since any clinical application would necessitate use past 5 days. 
Also, HADSCs have been proven to revert from a neural lineage after the neural 
induction process. Longer studies are required to ensure the non-induced group does 
not show this same behavior as the viability of the cells wanes.  Additionally, I would 
suggest combinations of NIM and MesenPRO media be utilized in the in vitro 
conditioning of the niche neural constructs. The evidence presented in this work shows 
significant evidence suggesting NIM induction yields faster differentiation while the non-
induced cells exhibit maintained differentiation and viability percentages nearing clinical 
relevance. A combination of these (ex. 1 day exposure to NIM followed by MesenPRO) 
may lead to more efficient niche neural construct preparation.    
 The goal of this research was to establish preliminary efficacy of this niche neural 
construct in stroke treatment applications. More in depth analyses are required to further 
confirm sensory/motor recovery and understand the regeneration observed in the 
construct region. More involved behavioral tests such as the adhesive removal test, food 
grabbing test, and NSS scoring system could be employed to achieve a better and more 
thorough representation of damage. Additionally, the researcher performing these 
analyses must be blind to the condition of the rats.  Another important consideration in 
the framework of the study is to include more control groups (scaffold only, and sham 
craniotomy) and overall larger animal numbers in order to achieve a higher degree of 
statistical relevance. Since there is significant evidence suggesting new matrix 
formation, analysis of neurotrophic factors and other neural matrix proteins would 
confirm that this newly formed matrix is actually brain matrix. A much longer study would 
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also allow for the establishment of a neural regeneration timeline. For example, a two-
week timeline is appropriate for analysis of skin regeneration; due to very minimal 
success in this area neural matrix regeneration has no generally accepted timeline. The 
vast abundance of neurons in the regenerated area begs the question: are these 
functional neurons. This research preliminarily suggests that are, but examination of 
more neuron-specific proteins such as sox2 and NeuN as well as an electrical 
examination or neurotransmitter release would prove very useful.  
 To further advance this research towards a translational application, I would 
suggest at least one study be completed where the niche neural constructs are prepared 
using autologous cells as opposed to human adipose derived stem cells. I would also 
suggest that minimally invasive methods of delivery be investigated, as minimally 
invasive procedures would be safer and overall more appealing to patient populations. 
Additionally, turning this scaffold into a manufacturable product will require further 
research, specifically investigating a shorter time line of decellularization. Initial efforts I 
would suggest include changing variables such as agitation speed as well as the shapes 
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Extra figure 1 clearly illustrates that the Map-2 expression previously shown is in 
fact co-localized with a cell nucleus. These images were provided as an additional 
measure to ensure the green fluorescence observed is in fact positive staining. This 
further confirms our previous conclusions that these cells are in fact expressing and 
maintaining the expression of the neuron marker Map-2. 
Extra figures 2 and 3 were provided to enable the viewer to directly compare the 
neural marker expression between groups. At lower magnification, it is clear the 
previously represented expression is representative. Extra figure 3 clearly portrays the 
developing extensions and projections of the cells and provides clearer evidence that the 











































Both figures 2 and 3 support the previously reported conclusions that we have 
replicated the neural induction process for human adipose derived stem cells seedded 
onto plastic. Up to the 5 day timepoint, these cells are morphologically changing and 
expressing key neural proteins. However,  by day 5 a lack of viable cell presence 
hinders analysis of protein marker expression, although extra figure 2 seems to indicate 
a degree of expression was still maintained.  





































Extra figure 4 illustrates the extreme morphological changes observed within the 
niche neural constructs. Cells appear to consist of one large cell body with extensive 
projections. These projections extend up to 450µm in some cases. The arrows point to 
such projections. The box at the right, outlines an entire cell, which morphological 
analysis dictates is phenotypically a neuron. This analysis further bolsters our claims that 
this niche neural construct can produce and maintain neurons.  
Extra Figure 3: Comparative matrix of in vitro studies at higher magnification. Morphological changes as well as the 


















Extra figures 5 and 6 provide further in depth analysis of the fate of the implanted 
HADSCs. Consistent with the previously presented IHC staining, there is no GFAP 
expression within the construct area. More significantly, we have confirmed the 






















Extra Figure 4: Live/Dead staining of niche neural constructs (representative of study 6, cells seeded onto scaffolds  
with no induction step where the media was replaced daily). The cells have formed large cell bodies with projections 
that elongate as much as 450µm. 
Extra Figure 5: Human mitochondria - GFAP Double Staining. Results are consistent with 
the IHC results presented in figure 62.Green indicates GFAP. Red indicates human 
mitochondria. Blue indicates DAPI nuclear staining. 
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a large portion of these implanted HADSCs express Map-2, indicative of commitment to 
a neuron lineage. To further confirm this and to very preliminarily assess the functionality 
of these neurons, expression of Synapsin I, a key protein involved in synaptic 
connections, was analyzed. As seen below, a significant amount of Synapsin I 
expression is observed, further confirming a neuron presence within the construct area 


























 Staining for myelin was another measure employed as a preliminary functional 
assessment of the neurons within the construct area. The patchy nature and overall 
faintness of the staining observed in the construct area does not permit any myelin-
based conclusions at this time. 
  
 
Extra Figure 6: Human mitochondria – Synapsin I Double Staining. Explants were stained 
for Synapsin I, a key protein of synaptic connections, as a preliminary assessment of the 
functionality of the neurons observed within the construct area. Green indicates Synapsin 


























Extra Figure 7: Luxol Fast Blue Staining for Myelin. Explants exhibit blue staining; however, the inconsistent and faint 
nature of staining could indicate a false positive or background staining. Overall, this preliminary myelin assessment is 
inconclusive.   
